Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

BACKGROUND: A phase II trial was performed to evaluate the efficacy of a dose-dense, 7 days on/7 days off schedule of temozolomide for patients with recurrent high-grade gliomas (HGG). METHODS: Sixty patients with recurrent HGG received temozolomide at 150 mg/m(2)/day on days 1–7 and days 15–21 duri...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Han, Seunggu J., Rolston, John D., Molinaro, Annette M., Clarke, Jennifer L., Prados, Michael D., Chang, Susan M., Berger, Mitchel S., DeSilva, Ashley, Butowski, Nicholas A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2014
Témata:
Clinical Investigations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4136897/
https://ncbi.nlm.nih.gov/pubmed/24670608
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou044
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky